Current understanding is that the practice isn't harmful (safety) and may benefit (efficacy), the two key concerns of drugs trials. See (from August 12, 2021):
"We don't know" alone is not a valid reason for discouraging a practice where there's no clear indication of harm and where understanding is being actively developed. There's an absolutely valid basis for taking a probablistic risk-based approach based on likely benefits vs. costs.